From: Masha Drokova < Sent: Friday, November 3, 2017 7:19 AM To: Jeffrey E. Subject: Re: what is investor type btw? w=at is one main quality for investor? On Nov 2, 2017, at 9:53 PM, jeffrey E. <[email protected] <mailto:jeevacation@g=ail.com» wrote: He is not an investor type . He is s p=rtner at a firm but used to be at Microsoft. Just use him for advice<=div> On Thu, Nov 2, 2017 at 11:13 PM Mas=a Drokova > wrote: =div> Thank you for the comprehensive feedback Steven. =div> <=iv>For me the main val=e is that the system is an order of magnitude cheaper than existing technol=gies, premised on leveraging data to help users see what daily elements are=affecting their blood sugar, and predicting dangerous highs and lows before=they happen so they can take actions beforehand. To date, their beta app has lowered b=ood sugar averages in over 55% of users 2x better than the world's most pre=cribed diabetes drug, Metformin. Which means that with the help of the date=diabetes would need to use less drugs. However I'd agree on complexity of regulations a=d saturation on the market. I run Day=One Ventures fund and based in San Francisco. I'd be happy to connect in pe=son sometime to learn about about your experience and tell about our invest=ents and opportunities I see. wrote: O= Nov 2, 2017, at 3:24 PM, Steven Sinofsky =blockquote type="cite"> Greetings Masha, I apologize for the delay. I was at some events in in UK w=ere I did not have connectivity. > > I have worked on a=related portfolio company so I will have to be a bit abstract on the specif=cs of this opportunity. So please excuse these brief thoughts. Also, t=e only information I had was what was provided in your mail which was limit=d relative to any detailed analysis. In general t=e challenge with glucose measurement is the finger prick. Any device that r=lies on this will only be marginally better than any other device, whether o= not there is software or a slightly more conve